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ABSTRACT
Advanced ovarian cancer is an incurable disease. Thus, novel therapies are 
required. We wished to identify new therapeutic targets for ovarian cancer. ShRNA 
screen performed in 42 ovarian cancer cell lines identified the centriolar replication 
factor STIL as an essential gene for ovarian cancer cells. This was verified in-vivo in 
orthotopic human ovarian cancer mouse models. STIL depletion by administration 
of siRNA in neutral liposomes resulted in robust anti-tumor effect that was further 
enhanced in combination with cisplatin. Consistent with this finding, STIL depletion 
enhanced the extent of DNA double strand breaks caused by DNA damaging agents. 
This was associated with centrosomal depletion, ongoing genomic instability and 
enhanced formation of micronuclei. Interestingly, the ongoing DNA damage was 
not associated with reduced DNA repair. Indeed, we observed that depletion of 
STIL enhanced canonical homologous recombination repair and increased BRCA1 
and RAD51 foci in response to DNA double strand breaks. Thus, inhibition of STIL 
significantly enhances the efficacy of DNA damaging chemotherapeutic drugs in 
treatment of ovarian cancer.




The SCL TAL1 Interrupting Locus (STIL, previously 
named SIL) protein is essential for the replication of 
centrioles, which are the core structures of centrosomes. 
Centrioles are important for chromosome segregation during 
mitosis and for the structure and function of primary cilia 
[1–4]. STIL is a 150KD protein conserved in vertebrates that 
is thought to act as a scaffold to many centrosomal, mitotic 
and cilia related proteins [5, 6, 7, 8]. STIL is expressed only 
in proliferating cells and its expression in cancer cells is 
associated with metastasis and worse prognosis. [9–13].
Ovarian cancers are often diagnosed at advanced stages 
with intraperitoneal spread. Although transient remissions 
may be achieved with chemotherapy, the prognosis of 
advanced ovarian cancer is grim [14]. Thus, newer therapies 
are needed. Centrosomes are often abnormal in cancer, 
including ovarian cancer [15–20] and centriolar amplification 
was recently shown to promote carcinogenesis [21]. Hence, 
centrosome-regulating proteins have been proposed as targets 
for therapy [17, 22–27]. Here we report that an unbiased 
shRNA screen identified STIL as essential for ovarian cancer 
cell survival. Using in-vitro and in-vivo orthotopic ovarian 
cancer pre-clinical models, we validated these findings and 
further show that STIL enhances the anti-tumor efficacy of 
DNA damaging chemotherapy. Thus, suppression of STIL 
may augment the effectiveness of current chemotherapeutic 
drugs used to treat this deadly malignancy.
RESULTS
STIL as a target for therapy of ovarian cancer
To identify potential new therapeutic targets in 
ovarian cancer, we analyzed whole-genome lentivirus-based 
shRNA dropout screens [28]. As mitosis is a proven target 
for ovarian cancer therapy [14, 15, 17, 20, 29], we were 
interested in identification of centrosomal genes essential 
for ovarian cancer cell growth. We observed that STIL was 
essential for growth in 10 of the 42 ovarian cancer cell lines 
tested. Furthermore, some inhibition of growth (blue at 
Figure 1A) was observed in most of the cell lines exposed 
to STIL shRNA. Ovarian cancer cells were more sensitive 
to the depletion of STIL than to other centriolar replication 
factors including PLK4, SASS6 and CENPJ (Figure 1A and 
Supplementary Table 1). Analysis of published TCGA data 
[30] revealed that STIL is ubiquitously expressed in ovarian 
cancer and that its mRNA levels significantly correlate with 
a more advanced histological grade (Figure 1B).
To validate the shRNA screen, we first confirmed the 
activity of STIL siRNA on ovarian cancer cell lines (for 
sequences see materials and methods and for confirmation 
of knockdown and activity see Supplementary Figure 1). 
We next evaluated the therapeutic efficacy of STIL siRNA 
in-vivo using well-characterized orthotopic ovarian cancer 
mouse models (Figure 2A) [15, 31, 32]. To simulate the 
treatment of advanced small-volume disease, therapy was 
initiated one week after tumor cell injection. We silenced 
STIL using intraperitoneal injection of STIL-specific siRNAs 
incorporated into DOPC nanoliposomes. Treatment with 
siSTIL-DOPC alone resulted in 69% (HeyA8) and 65% 
(IGROV1) reduction in tumor burden compared to siControl-
DOPC treated mice (Figure 2B, C). Animals treated with 
cisplatin alone (standard drug for treatment of ovarian cancer) 
showed 43% (HeyA8) and 47% (IGROV1) tumor reduction 
compared to siControl-DOPC treated groups. Combination 
therapy of siSTIL-DOPC with cisplatin showed a significant 
reduction of tumor burden (HeyA8- 83%; IGROV1- 95%) 
compared to siControl-DOPC treated mice (Figure 2B, C, 
p=0.004 for HeyA8 and p=0.028 for IGROV1 in 2-way 
ANOVA). There was no obvious toxicity noted in the animals 
during the course of treatment, as assessed by changes in 
Figure 1: STIL is highly expressed in ovarian cancer tumors and is essential for the survival of ovarian cancer cells. 
(A) Heatmap showing essentiality scores for four centriolar replication factors from 42 ovarian cancer cell line shRNA screens. Blue 
represents high essentiality (growth suppression) while red represents lower essentiality. STIL was essential in a higher proportion of cell 
lines than PLK4, while SASS6 and CENPJ were not found to be essential in the screens. (B) STIL mRNA levels (RNAseq) correlate with 
the histologic grade of ovarian cancer in the TCGA dataset, as determined using the cBioPortal (http://www.cbioportal.org).
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behavior, feeding habits, mobility and mean body weight 
(Supplementary Figure 2). Thus, siRNA suppression of STIL 
is effective for ovarian cancer therapy in-vivo.
STIL depletion enhances sensitivity to DNA 
damaging agents
The therapeutic cooperation between STIL siRNA 
and cisplatin observed in the preclinical cancer models 
(Figure 2) raised the possibility that STIL depletion 
enhances the sensitivity of ovarian cancer cells to 
DNA damaging agents. Indeed, knockdown of STIL 
significantly enhanced the sensitivity to cisplatin in 
HeyA8, IGROV1 and RMG1 ovarian cancer cells (Figure 
2D–2F) reducing the IC50 from a mean of 19µM (range: 
13.3-30µM) to 6µM (range: 3.3-10µM; P<0.01 two tailed 
T-test). In contrast, there was no treatment sensitization 
with the microtubule poison paclitaxel (Supplementary 
Figure 3). Thus, STIL knockdown sensitizes ovarian 
cancer cells to DNA damaging chemotherapy.
Given the above findings, we next examined 
whether STIL depletion enhances the DNA damage 
conferred by DNA damaging agents. Ovarian cancer 
cells were either transfected with siControl or with 
siSTIL and treated with 10μg/ml (33.3µM) cisplatin 
48h later. Cells were stained for γH2AX 3 and 6 hours 
after initiation of treatment with cisplatin. There was 
a significant increase in γH2AX foci in STIL depleted 
cells treated with cisplatin (Figure 3A–3B). As platinum 
compounds cause DNA double-strand breaks (DSB) 
only indirectly, we further examined the effect of STIL 
depletion on DNA damage caused by ionizing (X-ray) 
radiation (IR). γH2AX foci increased after treatment with 
IR of two different ovarian cancer cell lines in a dose 
dependent manner (Figure 3C and Supplementary Figure 
4). Similarly, we observed increased nuclear foci of 
p53-binding protein 1 (53BP1) in cells treated by STIL 
siRNA and IR (Figure 3D-E). Interestingly, there was 
a slight increase in γH2AX and 53BP1 foci after STIL 
siRNA alone (Figure 3A and 3D), suggesting that STIL 
may also be required for maintaining genome integrity. 
Together, these results suggest that STIL silencing 
enhances persistent DNA breaks-associated nuclear foci 
after exposure to DNA damaging agents.
Figure 2: Therapeutic cooperation between STIL depletion and cisplatin in ovarian cancer. (A) Illustration of the orthotopic 
models used for the in-vivo experiment: HeyA8 or IGROV1 cells were injected intraperitoneally (IP) to female nude mice. 8 days later, 
mice were divided into 4 groups and treatment was started by injecting siRNA/DOPC-nanoparticles (150µg/kg) twice a week and cisplatin 
(80µg/mouse) once a week intraperitoneally. Mice were treated for 4-5 weeks, sacrificed and tumors were excised and weighed. (B) Mean 
tumor weight in HeyA8 model, and (C) IGROV1 model. Values are means ± standard error. Main effect in 2-way ANOVA: p=0.004 for 
HeyA8 cells and p=0.028 in IGROV1 cells. (D) HeyA8 (E) IGROV1 (F) or RMG-1 cells were transfected with specific siRNA duplexes 
targeting the STIL gene (siSTIL) or with a non-specific siRNA control (siControl). 48h post transfection the cells were treated with different 
concentration of cisplatin for additional 48h. Then, cells viability was measured by MTT assay. Data show the means of two independent 
experiments (*, p<0.05; **, p<0.01; ***, p<0.001 Student two-tailed unpaired t-test).
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We and others have previously reported that STIL is 
essential for centrosomal replication and that its depletion 
causes centrosomal abnormalities manifested by decreased 
centrosomal number and abnormal mitoses [1, 2, 4] 
(Figure 4A, B and Supplementary Figure 5). Centrosomal 
aberrations caused by abnormalities in centrosomal genes 
result in small chromosomal segregation errors, leading to 
chromosomal aneuploidy [23, 33]. We therefore examined 
the effect of STIL depletion on chromosomal aneuploidy 
in ovarian cancer cells two days after transfection with 
siRNA against STIL (Table 1). Interphase fluorescent in 
situ hybridization (FISH) was independently performed 
for 12 chromosomes and the chromosomal numbers were 
determined in 400 cells per each probe (a total of 4800 
cells counted). Large deviations (≤2 or ≥6) in the modal 
number for specific chromosomes were detected for 8 of 
12 chromosomes in STIL knocked-down cells (Table 1 
and Supplementary Table 2, p < 0.05, Fisher’s exact test). 
Thus, depletion of STIL causes chromosomal aneuploidy.
Pellman et al reported that chromosomal mis-
segregation in mitosis causes DNA breaks and acquisition 
of DNA damage via the formation of micronuclei [34, 
35]. Consistent with these reports, an increased number of 
micronuclei was observed in IGROV1 cells treated with 
siSTIL and low dose IR (0.5-1Gy; Figure 4C-D, p< 0.05 for 
1Gy, two tailed T-test). Thus the enhanced DNA damage 
caused by STIL depletion may be explained by centrosomal 
abnormalities, chromosomal aneuploidy and enhanced 
micronuclei formation in response to IR.
STIL is not essential for major DNA repair 
pathways
The observation that STIL KD enhances 53BP1 and 
γH2AX foci 24h after induction of DNA DSB (Figure 3C, 
D) could be explained by either ongoing DNA damage 
(e.g. due to ongoing chromosomal missegregation) and/
or defects in DNA repair. BRCA1, a protein important 
Figure 3: STIL depletion enhances γH2AX and 53BP1 foci in response to DNA damage. (A) IGROV1 cells were transfected 
with siRNA targeting STIL or control, and 48 hrs later were treated by 10μg/ml cisplatin for 3 or 6 hr, after which cells were fixed and 
stained for γH2AX. Bar plots show the mean of two independent experiments, ± SEM, (*p<0.05; **p<0.01 in Student’s two tailed unpaired 
t-test). (B) Representative images of cells 3h after cisplatin treatment. Magnification x60. (C) Same as in (a), except IGROV1 cells were 
treated with increasing doses of ionizing irradiation instead of cisplatin. γH2AX foci (C) or 53BP1 foci (D) were counted 24h after 
irradiation in 200 cells from each treatment. The mean number of foci per cell is shown. *P<0.01, **P<0.05, ***P<0.001 in Student’s 
2-sided unpaired T-test. (E) Representative images of 53BP1 foci in cells 4hrs after IR. Magnification x60.
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in homologous recombination DNA repair (HRR), was 
reported to be localized to centrosomes [36, 37]. Ovarian 
cancers in patients with germline mutations in the BRCA1 
or BRCA2 genes are more sensitive to DNA damaging 
agents such as cisplatin [38, 39]. We thus hypothesized 
that STIL depletion and the consequent centrosomal 
defects phenocopy BRCA1 depletion. This “BRCAness” 
could have explained the increased sensitivity to DNA 
damage in the absence of STIL. To test this hypothesis, 
we confirmed the binding of BRCA1 to STIL by co-
immunoprecipitation in HEK293T cells (Figure 5A, B). 
To determine which domain of STIL binds to BRCA1 
we repeated the co-immunoprecipitations of HEK 293T 
cells co-transfected with BRCA1 and various STIL 
mutants [1, 2]. All these mutants interacted with BRCA1. 
This suggests that STIL and BRCA1 binding is probably 
mediated by STIL N terminal domain either directly or as 
part of a larger protein complex (Supplementary Figure 7).
Next, we asked if STIL depletion was sufficient to 
cause a state of “BRCAness”. HRR is mediated by BRCA 
and RAD51 proteins [40]. Upon DNA damage, BRCA1, 
BRCA2 and RAD51 bind to DNA breaks. Decreased 
reduction in RAD51 foci is characteristic of BRCAness 
[40]. We therefore examined the effect of STIL depletion 
on the number of RAD51 and BRCA1 foci after induction 
of DSB by IR. Surprisingly, we observed an increase in 
both RAD51 and BRCA1 foci in the STIL depleted cells 
(Figure 5C, D). These observations suggest that STIL is 
not necessary for BRCA1/RAD51-dependent DNA repair. 
Interestingly, similar to the slight increases in γH2AX 
and 53BP1 foci after treatment with STIL siRNA alone 
(Figure 3A and 3D), RAD51 foci were also evident in 
STIL-depleted cells even in the absence of irradiation 
(Figure 5C).
To further examine the effects of STIL on DNA 
repair, we determined the relative activity of the two main 
DNA repair pathways. U2OS cells bearing a single-copy 
integration of the reporters DR-GFP (HRR [41]), and EJ5 
(NHEJ [42]) were used to analyze the different DSB repair 
pathways. As a positive control, we used siRNA against 
CtIP, which is a regulator of end-resection required for 
homology-dependent DSB repair. RAD51-dependent HRR 
Figure 4: STIL silencing results in centrosomal aberrations and increased micronuclei following irradiation. (A, B) 
HeyA8 cells were seeded on coverslips, transfected with siRNAs and stained for γ-tubulin (green) and pericentrin (red) 48h post siRNA 
transfection to quantify centrosome number. Nuclei were stained with DAPI. Most si-Control treated cells have 2 centrosomes per cell 
and undergo bipolar mitosis (white arrow), while most cells silenced for STIL have 0-1 centrosome per cell and some of the mitoses are 
monopolar (yellow arrow). Magnification x100. Bar plots show the mean of three independent experiments, ± STDEV (**p<0.005 in 
Student’s two-tailed unpaired t-test.) (C) 48h post siRNA transfection, IGROV1 cells were irradiated (0.5, 1 and 2Gy), incubated for an 
additional 24h and then fixed and stained with DAPI. Micronuclei were counted in about 300 cells from each treatment, and the percentages 
of cells with1, 2 or more than 2 micronuclei were calculated. Shown is an average of two independent experiments. Two-tailed unpaired 
T-tests performed for the percentage of cells with more than 1 micronuclei: un-irradiated p=0.51, 0.5Gy p=0.06, 1Gy p= 0.025, 2Gy p= 
0.44. (D) Representative images of micronuclei (arrows) from si-STIL or si-control cells 24h after 1Gy IR. Magnification x60.
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was significantly increased in STIL-depleted cells (Figure 
6A, E). These findings are consistent with the staining for 
BRCA1/RAD51 foci. NHEJ was not significantly changed 
in STIL-depleted cells (Figure 6B). A dual reporter assay 
[43] (Figure 6C) confirmed a small but statistically 
significant increase in HRR in STIL knock-down cells 
(Figure 6D, P=0.01).
We previously showed that STIL depletion slows 
the transition between G2 to mitosis [9]. Indeed, STIL 
silencing in HeyA8 and IGROV1 cells increased the G2/M 
fraction in-vitro and in-vivo (Supplementary Figure 6).
Together, these results indicate that STIL silencing 
disrupts both the cell cycle checkpoints and the balance 
between the DNA damage repair pathways.
DISCUSSION
Despite significant activity of platinum and paclitaxel 
chemotherapy, advanced ovarian cancer is uniformly fatal 
[14]. Hence, novel therapies are urgently needed. Here, we 
report that STIL, a protein expressed in advanced ovarian 
cancer, may be such a novel therapeutic target.
STIL is one of the few mammalian proteins 
essential for de-novo centriolar formation and replication 
[1–4, 7, 44]. Centrosomes are often abnormal in cancer 
cells and centrosome amplification was shown to create 
chromosomal instability that promotes carcinogenesis and 
contributes to the aggressive behavior of ovarian cancer 
[18, 21]. Hence, centrosomal regulating proteins have been 
considered as targets for cancer therapy [22, 24, 25]. For 
example, we have previously shown that the centrosomal 
mitotic kinase SIK2 may be such a target [15].
Yet a recent study with a highly specific chemical 
inhibitor of PLK4, another critical centriolar replication 
factor, demonstrated that cancer cells can survive without 
centrioles [45]. Interestingly, in our shRNA screens 
(Figure 1A), PLK4 was essential for survival of a subset of 
ovarian cancer cell lines, suggesting a possible difference 
between enzymatic and non-enzymatic functions of PLK4. 
The importance of STIL as a scaffold for multiple proteins 
required for centrosome and cilia signaling, possibly 
explains why STIL was seen as the most essential in the 
shRNA screens of all centriolar replication factors (Figure 
1A). STIL, however, is not essential for survival of non-
neoplastic cells as demonstrated by the survival of STIL-/- 
embryonic stem cells and fibroblasts [1, 12].
We also observed that STIL depletion enhanced 
the extent of DSB caused by DNA-damaging agents, and 
ultimately, cytotoxicity. There is conflicting data regarding 
the potential association between centrosomal defects and 
Table 1: STIL silencing in IGROV1 cells results in chromosomal aneuploidy








Chromosome Si-Ctrl Si-STIL Si-Ctrl Si-STIL Si-Ctrl Si-STIL
#2 0 16 394 368 6 16 p<0.001
#4 4 10 394 375 2 15 p=0.001
#7 11 12 385 384 4 4 p=1.0
#8 2 12 392 372 6 16 p=0.002
#9 0 16 394 384 6 0 p<0.001
#10 37 39 361 348 2 13 p=0.013
#12 6 6 390 390 4 4 p=1.0
#15 0 20 394 378 6 2 p<0.001
#17 6 52 392 333 2 15 p<0.001
#18 37 5 361 382 2 13 p<0.001








Chromosome Si-Ctrl Si-STIL Si-Ctrl Si-STIL Si-Ctrl Si-STIL
#6 0 2 398 382 2 16 p<0.001
#X 0 0 374 380 26 20 p=0.448
IGROV1 cells were transfected with specific siRNA duplexes targeting the STIL gene (siSTIL) or with a non-specific siRNA 
as control (siCtrl). 48hrs post transfection the cells were collected and fixed, and FISH analysis for 12 chromosomes was 
performed according to a standard protocol [54]. 400 cells were counted for each chromosomal probe.
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DNA damage. Loss of centrosomes in non-transformed 
cells was not associated with increased sensitivity to DNA 
damaging agents [46, 47]. In contrast, Pellman’s lab has 
shown that in cancer cells, chromosomal missegregation 
caused by centrosomal abnormalities lead to the formation 
of micronuclei and to DNA damage. [34, 35, 48]. We show 
here that depletion of STIL in ovarian cancer cells caused 
chromosomal aneuploidy and the formation of micronuclei 
that might have caused the increased sensitivity to DNA 
damage.
The increased DNA damage in STIL-depleted 
cells exposed to DNA-damaging agents was unrelated 
to defects in DNA repair, or at least in the two major 
mechanisms of HRR and NHEJR. We have observed here 
that the proteins associated with HRR (BRCA1, Rad51) 
and NHEJ (53BP1) are retained in larger quantities upon 
STIL depletion. Consistent with these observations, HRR 
was increased in these cells. Interestingly, we demonstrate 
for the first time that STIL and BRCA1 are present in a 
protein complex. It is tempting to speculate that in the 
absence of STIL more BRCA1 is available for recruitment 
to DNA damage sites. Alternatively, the increased length 
of the G2 to M transition in STIL KD cells may increase 
the time available for DNA repair.
Several recent publications have highlighted the 
interplay between 53PB1, centrosomes loss and activation 
of p53 [49–51]. Specifically they demonstrated that 53BP1 
mediates p53-induced cell cycle arrest following centrosomal 
loss, by stabilizing p53. Yet it is unlikely that this pathway 
explains the cytotoxicity of STIL depletion in ovarian 
cancers. P53 is mutated in most ovarian cancers (including 
IGROV1) and we did not find any correlation between the 
essentiality of STIL in the shRNA screen (Figure 1A) and the 
status of P53 in the ovarian cancer cell lines.
Our most significant finding is that combination of 
weekly systemic cisplatin with intraperitoneal delivery of 
STIL siRNA was a highly effective therapy in two preclinical 
models of advanced ovarian cancer. As the first clinical trial 
with siRNA packed in DOPC is ongoing (NCT01591356), 
targeting STIL with siRNA may be clinically feasible.
Figure 5: STIL and BRCA1. (A, B) STIL interacts with BRCA1: Flag-STIL and BRCA1 were transiently co-expressed in 293T 
cells. 48h later, cells were harvested, lysed and the indicated protein was precipitated with an antibody (anti BRCA1 in A, anti STIL in B) 
followed by protein A/G agarose beads. BRCA1 and STIL were detected by western blot. Lys- whole cell lysate, NC- bead-only controls, 
without antibody, IP- precipitation with the indicated antibody. Shown is a representative of three independent experiments. (C, D) STIL 
silencing increases BRCA1 and RAD51 foci following irradiation. 48h post siRNA transfection, IGROV1 cells were treated with 2Gy IR 
and RAD51 foci (C) or BRCA1 foci (D) in cyclin A2-positive cells were counted at the indicated time-points in 50-90 cells from each 
treatment. The mean foci/cell is presented. (***p<0.0005 in a two-tailed unpaired T-test). Shown is a representative of two independent 
experiments performed. Bottom: representative foci images. Magnification x60.
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Figure 6: No major defects in repair of DNA double strand breaks (DSB) in STIL depleted cells. (A) Effect of the indicated 
siRNA in the gene conversion assay which measures classical, RAD51-dependent homologous recombination. (B) Effect of the indicated 
siRNA in an assay which measures NHEJ. (C) Schematic representation of the SeeSaw 2.0 reporters [43]. A GFP open reading frame (ORF) 
is flanked by two truncated parts of an RFP ORF (RF and FP) sharing 302bp of homologous sequence. Two I-SceI-target sites in opposite 
orientation are present at the 3’ end of the GFP ORF. After generation of a DSB by ectopic I-SceI endonuclease, repair via Non Homologous 
End Joining (NHEJ) results in cells that retain GFP expression. Alternatively, repair via Homologous Recombination (HR) leads to a 
functional RFP ORF. (D) Ratio of NHEJ to HR repair in U2OS cells following siRNA transfection. Effects of siRNA against STIL, si-
Control or against CtIP- a regulator of end resection required for homology-dependent DSB repair (positive control) are shown. The ratio of 
green to red cells in each condition was calculated. Increase NHEJ/HR ratio over the baseline value of 1.0 represents an imbalance between 
the two DSB repair pathways. An average of three experiments is shown (P=0.014 in Student’s paired T-test). (E) Validation of STIL or 




We used Flag-hSTIL and Flag-hSTIL deletion 
mutants in a lentiviral vector previously described [1]. 
pcDNA3-hBRCA1 was a kind gift of Dr. Ido Wolf.
Drugs
Cisplatin and paclitaxel were obtained from Teva 
Pharmaceutical Industries Ltd.
Antibodies
The following antibodies were used for western 
blot: rabbit anti STIL A302-441A1 (Bethyl Laboratories), 
mouse anti BRCA1 (Santa Cruz, sc-6954) and for loading 
controls mouse anti vinculin (Millipore MAB3574) and 
mouse anti alpha-Tubulin (Sigma T9026). Secondary 
antibodies were peroxidase-conjugated goat anti rabbit and 
goat anti mouse (Jackson Immunoresearch, #111-035-144 
and #115-035-146). The following antibodies were used for 
immunofluorescence: mouse anti gamma- tubulin (Abcam 
ab11316 and Sigma T5192), rabbit anti pericentrin (Abcam, 
ab4448), rabbit anti phospho Histone3 (Abcam, Ab32107), 
mouse anti ɣH2AX (Ser139, Merck-Millipore #05-636), 
rabbit anti 53BP1 (H-300, Santa Cruz, sc-22760), rabbit 
anti Rad51 (Calbiochem, #PC130), rabbit anti BRCA1 
(Millipore, #07-434) and mouse anti cyclinA2 ([6E6], 
Abcam, ab16726). Secondary antibodies were donkey anti 
rabbit Alexa Fluor 568 and donkey anti mouse Alexa Fluor 
488 (Invitrogen).
Cell culture
The HeyA8 human ovarian cancer cell line, was 
obtained from Dr. Isaiah Fidler (M. D. Anderson Cancer 
Center, Houston, TX). The IGROV1 and RMG-1 cell 
lines were obtained from the institutional Cell Line 
Core laboratory (MD Anderson policy ACA#1044). The 
IGROV1-CP20 cell line was developed by sequential 
exposure of the IGROV1 cell line to increasing 
concentrations of cisplatin. Cell line authentication was 
performed by the Cell Line Core Facility at The University 
of Texas MD Anderson Cancer Center at least once per year. 
IGROV1 (used for the in vitro experiments), 
IGROV1cp20 (used for the in-vivo experiments), HeyA8 
and RMG-1 cells were cultured in RPMI 1640 supplemented 
with 10% FCS at 37°C and 5% CO2 atmosphere.
RNA interference
In-vitro studies
For siRNA-mediated suppression of human STIL, the 
following oligonucleotide sequences were used: sequence 
“1207” 5’-GGGCTTGCTGTTTGCGATACATATT-3’ 
(Invitrogen) or sequence “STIL#1” 5’-GTTGTGAA 
CTGAGCGCTGA-3’ (Sigma). Mission siRNA Universal 
Negative Control #1 (Sigma) was used as a control. 
siRNAs were introduced into cells using SiImporter 
siRNA transfection reagent (Millipore, #64-101), 
according to the manufacturer’s instructions. 48h after 
transfection, cells were harvested for WB or RT-PCR 
analysis of STIL levels. For in-vivo delivery, siRNA 
oligos were incorporated into neutral liposomes (DOPC) 
as previously described [32].
The shRNA screens were performed as described 
previously [28]. Briefly, each cell line was infected 
with the RNAi Consortium (TRC) genome-wide 
lentiviral shRNA library at an MOI of 0.3. Cells were 
puromycin-selected, representative ‘T0’ samples were 
collected, and the remaining cells were split into three 
flasks. Triplicate cultures were then grown out for three 
to six passages, at which point genomic DNA was 
collected, shRNA barcode sequences were amplified 
by PCR, and hybridized to a custom microarray for 
quantification. Hairpin dropout scores (shRNA Activity 
Ranking Profile, or ’SHARP’ scores) were calculated 
as previously described [28] and combined into a Gene 
Activity Ranking Profile(‘GARP’) score. More negative 
GARP scores indicate a higher degree of essentiality for 
the targeted gene. STIL was determined to be essential 
where the GARP P-value was less than 0.05.
Immunostaining
For detection of ɣH2AX, 53BP1, RAD51, 
BRCA1 nuclear foci and micronuclei, cells were 
seeded on coverslips, transfected with siRNA against 
STIL or Control using SiImporter (described above), 
and 2 days later treated with a DNA-damaging agent 
(cisplatin or irradiation). Staining was performed as 
follows: Coverslips were washed in PBS, fixed in 4% 
Paraformaldehyde for 10 minutes and permeabilized in 
2% PFA and 0.5% Triton for 10 minutes. After washes in 
PBS and blocking in 10% Normal Donkey Serum (NDS) 
in PBST (PBS+0.5% Tween) for 45 minutes, they were 
incubated with primary antibodies (anti ɣH2AX 1:100, 
anti 53BP1 1:200, anti Rad51 1:500, anti BRCA1 1:2000 
and anti CyclinA2 1:100) for 2h in 10%NDS, washed 
in PBST and then incubated with secondary antibodies 
(donkey anti rabbit Alexa Fluor 568 and donkey anti 
mouse Alexa Fluor 488, both 1:1000) for 45 minutes in the 
dark. After washing with PBST they were mounted using 
ProLong Gold antifade reagent with DAPI (Molecular 
probes, #P36935). After 3 days, images of 50-300 cells 
from each treatment were taken and foci were counted 
using a Nikon fluorescence microscope.
For detection of the centrosomal markers gamma 
tubulin and pericentrin, staining was performed 48h after 
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siRNA treatment transfection as described above, except 
that fixation was done in methanol:acetone (1:1) at -20°C 
without the additional permeabilization step. Images 
were acquired using an Olympus IX81 fluorescence 
microscope, 100 cells were counted and analyzed for 
each experiment.
Co-immunoprecipitation
HEK293FT cells were co-transfected with Flag-
hSTIL and hBRCA1-encoding plasmids. 48h later, cells 
were lysed in immunoprecipitation buffer (10mM Tris pH 
7.5, 150mM NaCl, 0.5% Triton-X100) with fresh protease 
inhibitors (Complete mini, Roche), incubated 15 minutes 
on ice and centrifuged for 15 minutes at 12,000g. The 
supernatant was split into two tubes: “IP” containing the 
precipitating antibody (either anti STIL or anti BRCA1) 
and “NC” containing no antibody. The lysates were rotated 
gently overnight at 4°C. Then, 30μl protein A/G agarose 
beads (Santa Cruz) were added for an additional 1.5h at 
4°C to both the IP and negative control tubes. Samples 
were washed 4 times with NET- 2 washing buffer (50 
mM Tris-HCl, 150 mM NaCl), re-suspended in 40μl of 
sample buffer x1, denatured at 95°C for 5 minutes and 
analyzed by western blot using anti-BRCA1 and anti-STIL 
antibodies.
Chromosomal aneuploidy analysis
IGROV cells were transfected with specific 
siRNA duplexes targeting the STIL gene (siSTIL) or 
with a non-specific siRNA as control (siControl). 48h 
post transfection the cells were collected, fixed, and 
interphase Fluorescence in situ hybridization(FISH) 
analysis using Satellite probes of Vysis, (Vysis 
Downers, Grove, IL) for 12 chromosomes was 
performed according to the standard protocol detailed 
in [52]. Slides were analyzed using an Olympus BH2 
fluorescence light microscope equipped with a PlanApo 
100x/1.4 oil-immersion objective, an appropriate 
spectral filter (BH2-TFC1 Triple Band filter DAPI/
FITC/TRITC), and a 100W mercury arc lamp. 400 cells 
were counted for each probe.
In-vitro cytotoxicity experiments
For the combined experiments using siRNA and 
drug (cisplatin or paclitaxel), cells were seeded in 24 
wells at a confluence of 30% and transfected the next 
day as described in “RNA interference”. After 48h, 
drug was added to each well in duplicates, and 48h later 
viability was measured by counting viable cells under the 
microscope using trypan-blue, or using the MTT-based 
in- vitro toxicity assay(Sigma, TOX1), according to the 
manufacturer’s protocol.
For the combined experiments using siRNA and 
ionizing radiation, the same protocol was used except cells 
were irradiated in increasing doses in an X-ray irradiator 
(Kimtron Polaris® 320).
In-vivo studies
The female athymic nude mice for orthotopic 
ovarian cancer models were maintained as described 
earlier [31]. All mice were used in these experiments when 
they were 8 to 12 week old.
Long-term therapy experiments were performed 
using HeyA8 and IGROV1cp20 ovarian tumor models. 
Prior to injection, tumor cells were washed twice with 
PBS, detached by 0.1% cold EDTA, centrifuged for 5 
minutes and reconstituted in Hanks balanced salt solution 
(Invitrogen, Carlsbad, CA). Cell viability was confirmed 
by trypan blue exclusion. Tumors were established by 
intraperitoneal (i.p) injection of 250,000 (HeyA8) and 1.0 
x 106 (IGROV1cp20) cells.
To assess the effects of siRNA therapy on tumor 
growth, treatment was initiated one week after i.p. 
injection of tumor cells. Two different STIL siRNA 
sequences were used: STIL#1 for HeyA8 and STIL #1207 
for IGROV1cp20 as mentioned above. Mice were divided 
into 4 groups (n = 10 mice per group): (a) siControl-
DOPC, (b) siControl-DOPC + cisplatin, (c) siSTIL-
DOPC, and (d) siSTIL-DOPC + cisplatin. Mice were 
treated intraperitoneally with 150 μg/kgs iRNAs twice a 
week and cisplatin (80 μg/mouse) once weekly. Treatment 
was continued until mice in any group became moribund 
(typically 4-5 weeks following tumor cell injection). At 
the time of sacrifice, mouse weight, tumor weight, number 
of nodules, and distribution of tumors were recorded. 
Tumor tissue was harvested and either snap-frozen in 
liquid nitrogen for lysate preparation or fixed in formalin 
for paraffin embedding, or frozen in optimum cutting 
temperature medium (OCT; Miles, Inc., Elkhart, IN) to 
prepare frozen slides. The individuals who performed the 
necropsies, tumor collections, and tissue processing were 
blinded to the treatment group assignments.
To detect phospho Histone 3 (pH3) from frozen 
tumor tissues which were harvested 3days following 
siRNA treatment, frozen tumors were cut to 5 mm 
sections. Slides were dried for 30 minutes at room 
temperature, rehydrated in PBS for 5 minutes, fixed in 
ethanol at -20c for 10 minutes, incubated with blocking 
solution (5% normal goat serum and 0.5% Triton X-100 
in PBS) for 1 h, and then incubated with rabbit anti-pH3 
primary antibody for 4 h at room temperature. Slides were 
washed 3 times with PBS for 10 minutes and incubated 
with the secondary antibodies (Alexa Flour 568) for 2 h at 
room temperature, followed by mounting using ProLong 
Gold antifade reagent with DAPI (Invitrogen). 3 tumors 
from each group were analysed, images of 5 fields from 
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each tumor were photographed using an Olympus IX81 
fluorescence microscope.
Gene conversion, non homologous end joining 
(NHEJ) and recombination / NHEJ balance 
analysis
The analysis was performed as described previously 
[43]. Briefly, U2OS cells bearing a single copy integration 
of the reporters DR-GFP (Gene conversion;Homologous 
Recombination Repair, HRR [41]), EJ5 (NHEJ [42]) 
or SSR (NHEJ/recombination balance;[43]) were used 
to analyze the different DSB repair pathways. For each 
experiment, 60000 cells were plated in 6-well plates. 
One day after seeding, siRNA (si-control, si-CtIP or si-
STIL) transfection was performed using Lipofectamine 
(according to the manufacturer’s instructions). The next 
day, cells were infected with a lentivirus encoding the 
I-SceI endonuclease and labeled with Blue Fluorescent 
Protein (BFP) using a multiplicity of infection (M.O.I) of 
10. 24h later, the media was changed. The next day, cells 
were fixed using 4% paraformaldehyde and analyzed in a 
BD FACS Aria cell sorter. For the HRR/NHEJ balance, 
the ratio between green and red cells in each condition 
was calculated. Data represent a minimum of three sets of 
experiments performed in duplicates.
Cell cycle DNA content analysis
48h following siRNA transfection, HeyA8 and 
IGROV1 cells were collected, fixed in ice-cold EtOH 
over-night and stained the following day with Propidium 
Iodide (PI, Sigma P4864). Analysis was performed on the 
Gallios flow cytometer and data were elaborated using 
Kaluza software (Beckman Coulter).
Statistics
Data obtained from multiple experiments were 
reported as the mean ± SEM. Significance levels were 
determined by Student t test, analysis of variance 
(ANOVA) analysis or Fisher’s exact test (specifically 
indicated in each experiment).
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